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Novel analgesic ω-conotoxins from 
the vermivorous cone snail Conus 
moncuri provide new insights into 
the evolution of conopeptides
Silmara R. Sousa1, Jeffrey R. McArthur2, Andreas Brust1, Rebecca F. Bhola4, 
K. Johan Rosengren3, Lotten Ragnarsson  1, Sebastien Dutertre6, Paul F. Alewood1, 
Macdonald J. Christie  4, David J. Adams  2, Irina Vetter1,5 & Richard J. Lewis1
Cone snails are a diverse group of predatory marine invertebrates that deploy remarkably complex 
venoms to rapidly paralyse worm, mollusc or fish prey. ω-Conotoxins are neurotoxic peptides from 
cone snail venoms that inhibit Cav2.2 voltage-gated calcium channel, demonstrating potential for 
pain management via intrathecal (IT) administration. Here, we isolated and characterized two novel 
ω-conotoxins, MoVIA and MoVIB from Conus moncuri, the first to be identified in vermivorous (worm-
hunting) cone snails. MoVIA and MoVIB potently inhibited human Cav2.2 in fluorimetric assays and rat 
Cav2.2 in patch clamp studies, and both potently displaced radiolabeled ω-conotoxin GVIA (125I-GVIA) 
from human SH-SY5Y cells and fish brain membranes (IC50 2–9 pM). Intriguingly, an arginine at position 
13 in MoVIA and MoVIB replaced the functionally critical tyrosine found in piscivorous ω-conotoxins. 
To investigate its role, we synthesized MoVIB-[R13Y] and MVIIA-[Y13R]. Interestingly, MVIIA-[Y13R] 
completely lost Cav2.2 activity and MoVIB-[R13Y] had reduced activity, indicating that Arg at position 
13 was preferred in these vermivorous ω-conotoxins whereas tyrosine 13 is preferred in piscivorous 
ω-conotoxins. MoVIB reversed pain behavior in a rat neuropathic pain model, confirming that 
vermivorous cone snails are a new source of analgesic ω-conotoxins. Given vermivorous cone snails are 
ancestral to piscivorous species, our findings support the repurposing of defensive venom peptides in 
the evolution of piscivorous Conidae.
Cone snails are a diverse group of predatory marine invertebrates that deploy remarkably complex venoms to 
rapidly paralyse worm, mollusc or fish prey1. Each venom contains >1000 peptides1 named conopeptides or 
conotoxins, with venom complexity correlating with dietary breadth2. Most characterised conotoxins target ion 
channels in the peripheral and central nervous systems and muscle cells, providing a rich source of potent and 
selective molecules with potential to treat a variety of diseases, including pain3. ω-Conotoxin are a class of cono-
peptides in the knottin family that potently inhibit the mammalian neuronal Cav channels, including Cav2.23. 
Cav2.2 is highly expressed in the superficial layers of the spinal cord as well as dorsal root ganglion neurons where 
it plays an important role in pain signal processing4. Accordingly, ω-conotoxins that selectively inhibit Cav2.2 
produce anti-nociceptive (analgesic) effects when administered spinally in animals and humans5–8, including 
MVIIA (Prialt) from Conus magus, which is currently marketed for intrathecal use in the treatment of severe 
chronic pain5,9.
Most cone snails feed on polychaete worms, and reconstruction of their evolution supports the hypothesis that 
ancestral cone snails were vermivorous10–15. To-date, ω-conotoxins have only been reported in the venom of fish 
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hunting cone snails, where they were initially proposed to contribute to the “motor cabal” of conotoxins evolved 
for predation16 but more recently they have been identified as playing major defensive role17. Given ω-conotoxins 
were hypothesized to be repurposed from a defensive role in ancestral worm hunting species that facilitated a shift 
to fish hunting12, we used a Cav2.2 screen to identify two novel ω-conotoxins MoVIA and MoVIB in the venom of 
Conus moncuri, a western Pacific worm hunting (vermivorous) cone snail18,19. C. moncuri was initially considered 
a synonym of Conus litteratus (subgenus Elisaconus) but was recently recognized as a new species20 and placed 
in the Embrikena subgenus21. Interestingly, these new ω-conotoxins had an arginine at position 13 instead of a 
tyrosine previously shown to be crucial for ω-conotoxin activity22,23 and both preferentially targeted fish Cav2.2, 
suggesting ω-conotoxins play a defensive role in vermivorous cone snail species17.
Results
Assay-guided Isolation, Sequencing Alignment and Chemical Synthesis. C. moncuri crude venom 
(~250 ng/µL) fully inhibited hCav2.2 responses in SH-SY5Y cells (Fig. 1A). Two active fractions were isolated 
from C. moncuri crude venom (Fig. 1B) and sequenced, revealing two peptide sequences. Based on standard 
nomenclature, the peptides were named MoVIA (CKPOGSKCSOSMRDCCTTCISYTKRCRKYYN) and MoVIB 
(CKPOGSKCSOSMRDCCTTCISYTKRCRKYY). MoVIA and MoVIB are 31 and 30 amino acids in length, 
respectively, and contain a number of residues conserved in other ω-conotoxins, including lysine at position 2 
(K2), glycine at position 5 (G5), hydroxyproline at position 10 (O), and arginine at position 25 (R25) (Table 1). 
Whereas most previously described ω-conotoxins have an amidated C-terminus3, mass/sequence calculation 
indicated MoVIA and MoVIB lacked a C-terminal modification. The mass and elution time of synthetic MoVIA 
(3605.49 Da and 19.5 min) and MoVIB (3492.42 Da and 26.5 min) were identical to the corresponding isolated 
native peptides (Fig. 1C,D) and these synthetic peptides were used for further studies.
MoVIA Precursor Peptide Sequence. RACE PCR on the venom duct of C. moncuri identified a cDNA 
clone encoding a new ω-conotoxin precursor. The MoVIA pre-propeptide s eq ue nce ( MKLTCVVIVAVLFLTA
CQLITADDSRSTQRHRALRSTTKLSMSTRCKPPGSKCSPSMRDCCTTCISYTKRCRKYYN) comprising 76 
amino acid residues, including a 22 amino acid signal sequence (underlined), a 23 amino acid pre-propeptide 
region (italicized), and a mature peptide region (bolded). The signal sequence was 100% identical to a precursor 
peptide from the vermivorous C. pulicarius and 95% identical to other precursor peptides from the O1 superfam-
ily, including the vermivorous C. betulinus and the piscivorous MVIIA and GVIA. However, the mature peptide 
region was divergent from other ω-conotoxins, being only ~60% identical to GVIA, GVIIA and GVIIB, and 40% 
identical to MVIIA (see Fig. 2A, Table 1). Phylogenetic reconstruction of the untranslated and coding regions 
allowed the calculation of a cladogram tree (Fig. 2B), which shows MoVIA is most closely related to ω-conotoxins 
from piscivorous Conidae.
3D NMR Structure of MoVIB. In order to gain insight into the 3D structure, we subjected MoVIB to 
solution NMR spectroscopy studies at ultra-high field (900 MHz). The MoVIB NMR data were of high qual-
ity, with generally sharp line and distinct signal dispersion, consistent with a well-defined structure in solution. 
Collection of structural information from the data allowed calculation of the three-dimensional structure. From 
50 refined structures the 20 best, judged on energies, consistency with the experimental data and covalent geom-
etry (Fig. 3A, Table 2), were chosen to represent the MoVIB solution structure (PDB ID 6CEG; BMRB ID 30405).
The backbone structure of MoVIB (Fig. 3A) comprised a structural four-loop VI/VII framework cross-linked 
by disulfides to generate an ‘inhibitor cystine knot’ (ICK) motif reminiscent of other ω-conotoxins. The ICK, 
which features the three disulfides C1/C16, C8/C19, and C15/C26, is centered around a β-hairpin, which com-
prised residues 19–26 in MoVIB (Fig. 3A,B). The hydroxyl side chains from S6 and T17 form hydrogen bonds to 
the K7 and R27 backbone carbonyls, respectively. The two hydroxyprolines and one proline residue were all in a 
trans-conformation, based on 13C chemical shifts and sequential NOE patterns. Electrostatic mapping revealed 
that the MoVIB surface was highly charged (net charge +5.7) (Fig. 3C). The structures of GVIA, MVIIA and 
MVIIC (PDB ID code: GVIA, 1TTL; MVIIA, 1TTK; MVIIC, 1CNN), highlighting secondary structure, key phar-
macophore residues and surface features, are shown for comparison (Fig. 3B,C).
125I-GVIA Binding Assays. ω-Conotoxin GVIA from C. geographus is a high affinity Cav2.2 ligand24,25 that 
can be radiolabeled for binding assays26. MoVIA and MoVIB fully displaced 125I-GVIA from SH-SY5Y cell mem-
branes with similar potency (p < 0.001) to ω-conotoxins from piscivorous species (Fig. 4A,B, Table 3), suggesting 
they have overlapping binding site. Since MoVIA and MoVIB may have evolved for defense against fish predators, 
we determined if MoVIA and MoVIB could also displace 125I-GVIA from fish brain membranes. Consistent with 
this hypothesis, MoVIA and MoVIB displaced 125I-GVIA from fish brain with higher affinity than from human 
SH-SY5Y cell membranes (p < 0.05, two-way Anova) (Fig. 4, Table 3). Remarkably, MoVIA and MoVIB affinity 
for fish brain was significantly higher (p < 0.001) than ω-conotoxins from fish hunting species (Fig. 4B, Table 3).
MoVIA and MoVIB Selectively Inhibit hCav2.2 in Functional Assays. Consistent with results from 
the 125I-GVIA binding studies, MoVIA and MoVIB fully inhibited Cav2.2 responses in fluorimetric calcium imag-
ing assays in SH-SY5Y cells (Fig. 4C, Table 4). In contrast, both peptides were inactive (up to 30 µM) at endoge-
nous human Cav1.3 and Cav3.1 (data not shown), indicating selectivity for hCav2.
In rat dorsal root ganglia (rDRG) neurons, high voltage-activated (HVA) N-and P/Q-type calcium currents 
(Cav2.2 and Cav2.1 channels, respectively) contribute a major components of the endogenous calcium channel 
current27,28. In order to gain insight into the analgesic potential of MoVIA and MoVIB, we assessed their func-
tion on depolarization-activated Ba2+ currents in rat DRG neurons. MoVIA and MoVIB inhibited HVA cur-
rents in a concentration-dependent manner (Fig. 5A–C, Table 4). MoVIA inhibited ~34% of the whole-cell Ba2+ 
current that was not reversible following a 5-min washout, suggesting that these peptides have a slow off-rate. 
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Further inhibition of N-type calcium channels with a high concentration of CVIE (300 nM)29 after MoVIA (3 µM) 
had no further effect on Ba2+ current amplitude (Fig. 5B), indicating N-type calcium channel currents were 
fully inhibited by MoVIA. A saturating concentration of the P/Q-type Cav inhibitor ω-agatoxin (10 µM) applied 
after MoVIA (3 µM) inhibited further 20% of the residual Ba2+ currents (data not shown), consistent with the 
Figure 1. Assay-guided isolation of MoVIA–B from C. moncuri venom. (A) FLIPR calcium imaging assay. 
Crude venom from C. moncuri fully inhibited hCav2.2 responses in SH-SY5Y cells. (B) Inset shows the shell of 
C. moncuri (image courtesy of Dr. Josh Wingerd) (B) Reversed-phase HPLC chromatography separated two 
peaks eluting at 19.5 and 26.5 min (indicated by red arrows), which inhibited hCav2.2 activity in SH-SY5Y cells. 
(C,D) Extracted ion chromatograms of C. moncuri crude venom and synthetic peptides, confirming native 
MoVIA and MoVIB (red traces) coeluted with the synthetic forms (filled circles).
www.nature.com/scientificreports/
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percentage of P/Q-type current expressed in DRG neurons27,29, suggesting MoVIA had little effect at the P/Q-type 
currents endogenously expressed in rDRG.
Role of Position 13 in ω-Conotoxins. Tyrosine at position 13 (Y13) has previously been shown to be 
essential for high affinity interactions of piscivorous ω-conotoxins at Cav2.222,23,30,31. In contrast, MoVIA and 
MoVIB maintain high Cav2.2 affinity despite having an Arg (R13) instead of tyrosine at this key position. To 
investigate the structure-function at position 13, we synthesized and characterized MoVIB-[R13Y] and MVIIA-
[Y13R]. NMR-derived secondary shifts of MoVIB-[R13Y] and MVIIA-[Y13R] were not significantly different 
from the corresponding native peptides (Fig. 6A,B), indicating that these replacements did not perturb the overall 
structure or fold.
In patch clamp assays using rat DRG, the potency of MoVIB-[R13Y] was ~5-fold lower compared to MoVIB 
(see Table 4). This result was supported by both fluorimetric calcium imaging and binding assays in SH-SY5Y 
cells, where the potency of MoVIB-[R13Y] was ~10-fold lower than wild type MoVIB (Table 4). In contrast, in 
calcium imaging assays using SH-SY5Y cells, MVIIA-[Y13R] was inactive at concentrations up to 30 µM (Table 4).
Conotoxin Amino Acid Sequencea
MoVIA CKPOGSKCSOSMRDCCTT–CISYTKRCRKYYN
MoVIB CKPOGSKCSOSMRDCCTT–CISYTKRCRKYY–
GVIA CKSOGSSCSOTSYNCCRS–CNOYTKRC–Y*– –
GVIIA CKSOGTOCSRGMRDCCTS–CLLYSNKCRRY– –
GVIIB CKSOGTOCSRGMRDCCTS–CLSYSNKCRRY– –
MVIIA CKGKGAKCSRLMYDCCTGSCRSGK–C*– – – – –
Table 1. Related ω-conotoxin sequence alignments. aAlignment generated manually with labeling scheme 
according to physicochemical criteria: Hydrophobic amino acids in bold (C, P, M, I, Y, L, A), acidic in italic (D), 
basic in underline (RK), hydroxyl + amide + Gly in bold/italic (G, S, T, N) and PTM in bold/underline (O for 
hydroxyproline). *Amidated C-terminus.
Figure 2. MoVIA precursor sequence and alignment. (A) Alignment of MoVIA precursor sequence with other 
conotoxins sequences belonging to the O1-superfamily. RACE PCR for cloning and amplification of the cDNA 
ends, using mRNA extracted from C. moncuri venom duct, identified a MoVIA nucleotide sequence of eighty-
seven base pairs. The MoVIA precursor sequence was predicted through reverse translation using Expasy tools. 
(B) Cladogram tree generated in Jalview v2.8, with the tree roots show average distances. This cladogram reveals 
ω-MoVIA and ω-MoVIB are most closely related to ω-conotoxins from fish hunting cone snails.
www.nature.com/scientificreports/
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Intrathecal MoVIB in a Rat Model of Neuropathic Pain. At days 10–11 post partial nerve ligation 
(PNL) surgery, rats developed a significant (p < 0.001) decrease in the PWT (paw withdrawal threshold; value 
of 0.6 ± 0.7 g, n = 24) compared to pre-surgery baseline (14.2 ± 1.6 g) (Fig. 7A), confirming the establishment 
of mechanical allodynia indicative of PNL-induced neuropathic pain. Intrathecal MoVIB dose-dependently 
reversed PWT (ED50 0.04 ± 0.01 mol) associated with mechanical allodynia, at 0.1–1 nmol doses (n = 3–4, 
p < 0.01 one-way ANOVA) and this effect was irreversible over the first 4 h (p < 0.01–0.0001; two-way ANOVA) 
(Fig. 7A).
To quantify side effects of MoVIB we used a visual scoring method. MoVIB doses of 0.1–1 nmol produced 
effects on visual side effect scoring method that were significantly different from vehicle (p < 0.05; one way 
ANOVA) whereas the lower doses (0.01–0.03) produced no significant effect. The development of side effects 
was dose-dependent (ED50 0.09 ± 0.05 nmol, Fig. 7B) and irreversible, lasting for up to 4 h (p < 0.0001; two-way 
ANOVA). The MoVIB therapeutic index, calculated as the ratio of the ED50s for the visual side effect score rela-
tive to mechanical PWT was 2.2, indicating a narrow safety window (Fig. 7C) though improved over the safety 
window for MVIIA (ED50 of 0.04 nmol and a TI of 0.7)32.
Discussion
Cone snails have evolved different cabals comprising groups of venom peptides with complementary or syner-
gistic pharmacology to facilitate prey capture33–35. Piscivorous cone snails use ω-conotoxins to inhibit vertebrate 
Cav2.2 as part of a ‘motor cabal’ that blocks neuromuscular transmission and immobilizes fish16,35. Recently, 
ω-conotoxins were hypothesized to have evolved originally for defence by ancestral vermivorous species and later 
repurposed for fish hunting12. In the search for potential ancestral ω-conotoxins in worm-hunting species, we iso-
lated two potent vertebrate-active ω-conotoxins from the venom of the vermivorous Conus moncuri18, suggesting 
that ω-conotoxins could have indeed evolved originally for defence in ancestral worm hunting species.
All venom peptides, including ω-conotoxins, are subjected to evolutionary pressures that enhance ances-
tral activities where they provide a competitive advantage10–15. Consistent with this view, similar evolutionary 
Figure 3. 3D NMR solution structure of MoVIB and comparison with related ω-conotoxins structures. (A) 
Stereoview superposition of the family of 20 structures representing the MoVIB solution structure. (B) MoVIB 
backbone and side chains presented in a ribbon and ball-and-stick format, and compared to the GVIA, MVIIA 
and MVIIC structures. Highlighted are the residues identified as important for their pharmacophores, including 
Y13 (Tyr13) and K2 (Lys2). Disulfide bonds are shown in yellow (C) Electrostatic surfaces of MoVIB, GVIA, 
MVIIA and MVIIC. Positively charged residues are shown in blue and negatively charged residues in red.
www.nature.com/scientificreports/
6SCIeNTIFIC REPORTS |  (2018) 8:13397  | DOI:10.1038/s41598-018-31245-4
pressures likely also account for the highly potent ω-conotoxins found in vermivorous species. The close relat-
edness of vermivorous to piscivorous ω-conotoxin signal and propeptide sequences suggest they have related 
evolutionary origins and target related species. Since vermivorous cone snails are ancestral to piscivorous spe-
cies36, this sequence relatedness confirms the potential for vertebrate-active ω-conotoxins in ancestral vermivo-
rous to have evolved originally for defence against fish and to be later repurposed for fish hunting in piscivorous 
Conidae. However, MoVIA and MoVIB have an Arg13 replacing the functionally critical Tyr13 found in potent 
Cav2.2 inhibitors from fish hunting species. Despite this important sequence difference, MoVIA and MoVIB 
potently displaced the prototypical ω-conotoxin GVIA from human SH-SY5Y cell membranes, indicating that 
vermivorous and piscivorous ω-conotoxins share an overlapping binding site. Interestingly, MoVIA and MoVIB 
displaced GVIA from fish brain membranes with even higher affinity and were more potent at fish calcium chan-
nels than GVIA and MVIIA from piscivorous Conidae. These data support MoVIA and MoVIB being positively 
selected to target Cav2 in predatory fish as part of a defensive strategy, reminiscent of the δ-conotoxins found in 
the lightning-strike cabal of fish hunters that are also used defensively by other vermivorous cone snail species37.
In rat DRG neurons, N- and P/Q-type calcium channel currents are the predominant HVA calcium currents28. 
At saturating concentrations, MoVIA and MoVIB fully inhibited N-type (Cav2.2) channels currents in rat DRG 
cells without significantly affecting P/Q-type (Cav2.1) channels. Moreover, in human SH-SY5Y cells both MoVIA 
and MoVIB (30 µM) failed to inhibit Ca2+ influx associated with endogenously expressed Cav1.3 and Cav3.1. 
These findings position MoVIA and MoVIB as selective Cav2.2 inhibitors, with similar pharmacological profile to 
the Cav2.2-selective ω-conotoxins from piscivorous cone snails. Whereas the exact amino acid residues involved 
in selectivity remain incompletely defined, MoVIA and MoVIB contain a hydroxyproline at position 10 that 
Parameters Energies (kcal/mol)
Overall −986.6 ± 31.6
Bonds 18.37 ± 1.40
Angles 56.18 ± 6.55
Improper 20.93 ± 2.44
Van der Waals −104.3 ± 5.39
NOE 0.265 ± 0.019
cDih 0.179 ± 0.130
Dihedral 138.4 ± 1.75
Electrostatic −1116.7 ± 33.8
MolProbity Statistics
Clashes (>0.4 Å/1000 atoms) 8.28 ± 3.44
Poor rotamers 0.37 ± 1.14
Ramachandran Outliers (%) 0.19 ± 0.86
Ramachandran Favoured (%) 92.31 ± 1.25
MolProbity score 1.93 ± 0.14
MolProbity score percentilea 78.6 ± 6.86
Residues with bad bonds 1.43 ± 1.79
Residues with bad angles 0.00 ± 0.00
Atomic RMSD (Å)
Mean global backbone (residues 1–28) 0.59 ± 0.19
Mean global heavy (residues 1–28) 1.26 ± 0.23
Distance Restraints
Intraresidue (i-j = 0) 101
Sequential (/i-j/ = 1) 105
Medium range (/i-j/ < 5) 40
Long range (/i-j/>5) 97
Hydrogen bonds 6 (for 3 H-bonds)
Total 349
Dihedral angle restraints
φ 9
Ψ 8
χ1 15
Total 32
Violations from experimental restraints
Total NOE violations exceeding 0.3 Å 0 (highest 0.275)
Total Dihedral violations exceeding 3.0° 0 (highest 1.97)
Table 2. Energies and structural statistics for the family 20 structures of MoVIB with the best overall 
MolProbity score.
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is often found in Cav2.2-selective peptides38,39. The reduced activity of MoVIA and MoVIB observed in Cav2.2 
functional vs. binding assays are well known for ω-conotoxins and have been attributed to the non-physiological 
conditions used to enhance ligand affinity in binding assays31. Alternatively, the presence of Cav2.2 auxiliary subu-
nits in the functional assays vs. their potential absence in binding assays may contribute to differences in potency, 
given ω-conotoxins have reduced affinity in the presence of the auxiliary α2δ subunit24,29,40,41.
Figure 4. 125I-GVIA Radioligand Binding and Functional calcium imaging assays. (A,B) MoVIA and MoVIB 
displaced 125I-GVIA from (A) SH-SY5Y cell and (B) fish brain membranes. (C) Concentration-response curves 
for ω-conotoxins MoVIA, MoVIB, GVIA and MVIIA. Data was calculated as mean ± SEM, n = 3–6 wells from 
3–4 independent experiments. IC50s are given in Tables 3 and 4.
www.nature.com/scientificreports/
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To better understand the structure-function of these new vermivorous ω-conotoxins, we used NMR spectros-
copy to determine the tertiary structure of MoVIB. Overall, the tertiary structure of MoVIB was similar to those 
of fish hunting ω-conotoxins, comprising six cysteines connected 1–4, 2–5, 3–6 to display four loops to match 
the VI/VII framework. MoVIB retained a number of residues in and around the ω-conotoxins pharmacophore3, 
including a significant number of positive (K2, K7, R13, K24, R25, R27 and K28) and hydrophobic (M12, I20, 
Y22,Y29, T30) residues. Comparing the NMR structures of MoVIB with those of other ω-conotoxins (Fig. 3) 
showed that Arg13 was oriented similarly to Tyr13 in MVIIA, GVIA and MVIIC, suggesting it may interact with 
a similar part of the pharmacophore perhaps also through hydrogen bonding interactions22,30,31.
Interestingly, MoVIA has an elongated C-terminus, with a Tyr30 and Asn31 in the last two positions, whereas 
the less potent MoVIB sequence finishes at Tyr30, indicating that Asn31 contributes to the higher affinity of 
MoVIA for Cav2.2. Indeed, Asn31 is located near loop 4 that contributes to the ω-conotoxins pharmacoph-
ore42, with the most potent ω-conotoxins having an amidated C-termini22,24 and de-amidation reducing GVIA 
potency31. Therefore, it is conceivable that the side chain or backbone amide of Asn31 in MoVIA could mimic the 
contribution of the amidated C-terminus found in other ω-conotoxins. Despite Arg13 replacing the conserved 
Tyr13 critical for potent Cav2.2 inhibition in piscivorous ω-conotoxins22,23, the pharmacology of MoVIA and 
MoVIB closely resembles that of ω-conotoxins from fish-hunting cone snails, including those from C. consors, 
C. catus, C. fulmen, C. geographus, C. magus, C. radiatus, C. striatus and C. tulipa22,23,38,43,44. Indeed, MoVIA and/
or MoVIB may be ancestral to GVIIA and/or GVIIB, given Tyr13 is also replaced by Arg13 and both have sim-
ilar elongated and non-amidated C-termini, albeit those from C. geographus are ~100-fold lower affinity than 
the highly homologous GVIA at mammalian Cav2.216,45. Similarly, the MVIIA-[Y13R] analogue also showed 
~100-fold decrease in binding affinity over MVIIA and no functional activity at mammalian Cav2.2. In contrast, 
the MoVIB-[R13Y] analogue failed to show enhanced binding affinity and potency to inhibit calcium influx in 
FLIPR assays and rat DRG neurons. Since NMR data indicates that MoVIB-[R13Y] and MoVIB have similar 
structures, it appears that Arg13 may be uniquely preferred to Tyr13 in vermivorous ω-conotoxins.
Consistent with Cav2.2 being a validated analgesic target, rat behavioural studies using the PNL model of neu-
ropathic pain confirmed the MoVIB analgesic activity. Intrathecal injection of MoVIB accompanied side effects 
common to ω-conotoxins, including shaking, tail twitching and serpentine tail movement, indicating that MoVIB 
would likely need to be carefully titrated intrathecally in a clinical setting to manage dose-limiting side effects also 
seen for ω-conotoxins MVIIA and CVID46. Nonetheless, we calculated an apparently improved safety window for 
MoVIB compared to that published for MVIIA32, which is currently marketed. Future studies will investigate the 
activity and the therapeutic index of MoVIA and MoVIB in other clinically relevant models of pain.
In conclusion, we have discovered and pharmacologically characterized two novel ω-conotoxins from the 
venom of a vermivorous cone snail, Conus moncuri. ω-MoVIA and ω-MoVIB had highest affinity for fish Cavs, 
suggesting they were positively selected for defense against predation in this worm-hunting species. Given vermi-
vorous cone snails are ancestral to piscivorous species, this finding supports the repurposing of defensive venom 
peptides during the evolution of piscivorous Conidae, as proposed previously17. Alternatively, MoVIA and MoVIB 
may be an example of convergent evolution of distantly related cone snail toxins that target similar pharmacology 
in different organisms47,48, although the striking structural and sequence similarities suggest otherwise. Like two 
modestly potent piscivorous ω-conotoxins GVIIA and GVIIB, these vermivorous ω-conotoxins possess an Arg13 
instead of the otherwise critical Tyr13, providing new insight into the structural features required for high-affinity 
interactions of ω-conotoxins at Cav2.2 channels.
Methods
Drugs and Chemicals. All drugs and chemicals were analytical reagent grade sourced from Sigma Aldrich, 
NSW, Australia, unless otherwise detailed throughout the text (in parentheses).
ω-Ctx Human SH-SY5Y Membrane Fish brain Membrane
MoVIA 0.035 ± 0.017 0.004 ± 0.002
MoVIB 0.365 ± 0.204 0.006 ± 0.001
GVIA 0.078 ± 0.012 0.160 ± 0.086
MVIIA 0.068 ± 0.001 0.094 ± 0.042
Table 3. IC50 ± SEM (nM, N = 3) for displacement of 125I-GVIA binding.
ω-Conotoxin
SH-SY5Y fluorimetric 
hCav2.2 assay (n = 3)
rDRG neuron N-type 
currents (n = 5)
MoVIA 0.33 ± 0.018 0.08 ± 0.01
MoVIB 0.60 ± 0.12 0.18 ± 0.03
MoVIB-[R13Y] 3.47 ± 0.55 0.90 ± 0.13
GVIA 0.17 ± 0.025 0.1040
MVIIA 0.024 ± 0.005 0.05227
MVIIA-[Y13R] Inactive at 30 µM ND
Table 4. IC50 ± SEM (μM) for ω-conotoxin inhibition of Cav2.2. ND = Not determined.
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Venom Extraction. Crude venom was stored at 4 °C for immediate use, or at −20 °C for long-term stor-
age. Prior to fractionation crude venom was re-suspended in 30% acetonitrile/water (ACN/H2O; Sigma Aldrich, 
NSW, Australia), acidified with 0.1% trifluoroacetic acid (TFA) and centrifuged at 10,000 x g for 5 min. Soluble 
material was lyophilized and re-dissolved in 5% ACN/H2O. Protein content was estimated by measuring the 
absorbance at 280 nm (E280) using a Nanodrop (Thermo Scientific).
Figure 5. Inhibition of high voltage-activated (HVA) calcium channel currents in isolated rat DRG neurons. 
(A) Superimposed depolarization-activated whole-cell Ba2+ currents elicited by 75 ms voltage steps to 0 mV 
from a holding potential of −70 mV. (B) The current traces labelled correspond to time at which the Ba2+ 
current was recorded as indicated in (B). (B) Time course of experiment (in A), with peak inward current 
amplitude plotted every 10 sec in the presence of increasing concentrations of MoVIA (30 nM–1 µM) followed 
by 300 nM CVIE. (C) Concentration-response relationships obtained for MoVIA, MoVIB and MoVIB-[R13Y]. 
Data points represent mean ± SEM of 5 independent experiments. IC50s are given in Table 4.
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Assay-Guided Isolation of MoVIA and MoVIB. Crude venoms were screened for Cav2.2 activity using 
the human SH-SY5Y neuroblastoma cell line and the FLIPRTETRA (Fluorescent Imaging Plate Reader, Molecular 
Devices, CA, USA) calcium imaging assay, as described previously40. Two Cav2.2 inhibitors were isolated using 
Reversed Phase High Performance Liquid Chromatography (RP-HPLC) on a Vydac 218TP C18 (250 × 4.6 mm, 
5 μm) analytical column. Fractions eluted at 0.7 ml/min with a linear gradient of 0–100% solvent B over 60 min 
(solvent A: 90% water, 0.1% formic acid; solvent B, 90% acetonitrile, 10% water, 0.09% formic acid) on a Dionex 
UltiMate® 3000 LCi solvent delivery system (Thermo Scientific). Fractions were collected on a Gilson FC204 
(Gilson) fraction collector and lyophilized. Dried fractions were re-dissolved in physiological salt solution (PSS) 
assay buffer (composition in mM: NaCl 140, Glucose 11.5, KCl 5.9, MgCl2 1.4, NaH2PO4 1.2, NaHCO3 5, CaCl2 
1.8, HEPES 10) and tested for Cav2.2 channel activity in SH-SY5Y cells using the FLIPR platform.
Active Cav2.2 inhibitor fractions were analyzed for purity by liquid chromatography/mass spectrometry (LC/
MS) and their molecular weights determined using a matrix-assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) mass spectrometry system (4700 Proteomics Analyzer, Applied Biosystems, Mulgrave, Australia), 
with an α-cyano-4-hydroxycinnamic acid matrix (CHCA [5 mg/mL]; Sigma Aldrich).
Peptide Sequencing. We obtained the MoVIA and MoVIB N-terminal sequences using automated Edman 
degradation (Australian Proteome Analysis Facility) on a 494 Procise Protein Sequencing System (Applied 
Biosystems). The MoVIA and MoVIB samples were dissolved in urea (4 M) and ammonium bicarbonate 
(50 mM) and reduced using dithiothreitol (100 mM) at 56 °C for 1 h under argon. Then alkylated with acryla-
mide (220 mM) for 30 min in the dark, and reaction quenched by the addition of an excess of dithiothreitol. The 
sample mixtures were desalted by reverse RP-HPLC and collected fractions dried using a SpeedVac concentrator 
(Thermo Scientific). Subsequently, samples were loaded onto pre-cycled bioprene discs and subjected to 35 cycles 
of Edman degradation for N-terminal sequencing.
Figure 6. Hα secondary chemical shifts of MoVIB, MoVIB-[R13Y] and MVIIA-[Y13R]. The secondary 
Hα chemical shifts were determined by subtracting the shifts observed in random coil peptides from the 
shifts determined from the 2D NMR analysis. (A) Native MoVIB and the mutant MoVIB-[R13Y] (B) native 
MVIIA and the MVIIA-[Y13R]. Similar conformations for native and mutant peptides are evident from small 
deviations in chemical shifts, which are highly sensitive to structural changes.
www.nature.com/scientificreports/
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RNA Extraction and RACE PCR. C. moncuri venom duct (1 mg) was carefully removed on ice, immedi-
ately placed in RNAlater® (Ambion, NSW, Australia) and kept at 4 °C. On the day of RNA extraction, the tissue 
was grounded and homogenized. Total RNA extraction was carried out using TRIZOL Reagent kit (Invitrogen, 
CA, USA), accordingly to the manufactures’ instructions. Isolated RNA was subsequently treated with RNase/
Figure 7. MoVIB effects on a rat partial nerve ligation model. (A) Intrathecal MoVIB significantly reversed 
mechanical allodynia in the PNL model (n = 3–6), in a dose dependent manner (ED50 0.04 ± 0.01 nmol). 
Analgesic effect lasted for up to 4 h. (B) MoVIB side effects demonstrated using the rotarod. (C) Visual side 
effect score (0 = nil, 1 = mild, 2 = moderate, or 3 = severe) demonstrated that intrathecal MoVIB causes dose 
dependent side effects (ED50 0.09 ± 0.05 nmol), with no significant improvement over 4 h (p > 0.05). (D) Dose 
response curves plotted for intrathecal MoVIB for calculation of the therapeutic index (TI) and safety window. 
ED50 data was calculated on PWT as 50% MPE and visual side effect score. Values denote mean ± SEM.
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DNase-free kit (Qiagen, Hilden, Germany) to remove any genomic DNA contamination. RNA concentration was 
determined by absorbance measurements at 260 nm. RNA purity/integrity was assessed by analyzing the ratio 
260/280 nm using a NanoDrop (Thermo Scientific, MA, USA).
The resulting cDNA was used as template in a polymerase chain reaction (PCR). Primers used on RACE 
PCR were designed based on previously published sequences from members of the O-superfamily of vermi-
vorous Conidae49. The 3′ RACE first strand cDNA was synthesized from 1 μg total RNA using FirstChoice 
RLM-RACE kit (Ambion), following the manufacturer’s instructions. Primer sequences were F1 = 
5′-CATCGTCAAGATGAAACTGACGTG-3′ and R1 = 5′-CACAGGTATGGATGACTCAGG-3′. PCR reac-
tion with 500 ng of cDNA as template was performed using FastStart Taq DNA polymerase (Roche, Basel, 
Switzerland), under the following cycling conditions: 95 °C for 4 min, followed by 40 cycles of 95 °C for 30 s, 
58 °C for 30 s, and 72 °C for 1 min and a final elongation step at 72 °C for 7 min. PCR products were analysed and 
purified after separation on a 1% agarose gel, using a QIAquick Gel Extraction kit (Qiagen). Gel extracted PCR 
products were sequenced at the Australian Genome Research Facility (AGRF), using the forward and reverse 
primers F1 and R1, respectively. Sequencing data was transferred to Expasy Tools50 for sequence translation and 
amino acid sequence prediction. Sequences from other conotoxins belonging to the O-superfamily were retrieved 
either from GenBank51 or Conoserver52 and compared with MoVIA. Sequence alignment was performed using 
Clustal W53 and Jalview version 2.854.
Chemical Synthesis of MoVIA and MoVIB. Synthesis of MoVIA, MoVIB and analogues were performed 
using in situ neutralization Boc-SPPS on a Boc-Asn-PAM or Boc-Tyr-PAM resin employing HBTU/DIEA activa-
tion, respectively, as described previously55. Assembled peptidyl-resin was cleaved with hydrogen fluoride for 1 h 
using p-cresol/p-thio-cresol scavenger (10%) and crude peptide precipitated from ether, filtered and lyophilized 
from acetonitrile/H2O. After HPLC clean up, pure reduced peptides (20 mg each/[0.2 mg/mL]) were oxidized 
at pH 7.8 in a solution of 0.3 M NH4OAc/0.3 M guanidine-HCl in the presence of GSH/GSSG (100:10 mol eq). 
Two major peptide isomers were obtained after RP-HPLC in quantities of 1–2 mg, corresponding to MoVIA and 
MoVIB.
Mass Spectrometry. LC-ESI-MS/MS was performed on synthetic MoVIA and MoVIB samples separated 
on a ZORBAX 300SB-C18 (2.1 × 100 mm × 1.8 µm) column, eluted with a Shimadzu 30 series HPLC system 
at 400 μl/min, with a linear gradient from 1–80% over 25 min. The eluent was analysed on a tripleTOF 5600 
mass spectrometer (ABSCIEX, MA, USA) with a quadruple TOF system and a DuoSpray ionisation system. 
The ion-spray voltage was set to 5300 V, with full scanning over 250 ms, followed by full scan product ion data 
obtained in the information dependant acquisition (IDA) mode over 20 × 50 ms. The mass range was set to 300–
4000 (m/z) for TOF MS mode and 80–4000 (m/z) for full scan TOF MS/MS mode. Buffer A was 0.1% FA and 
buffer B was 90% acetonitrile/0.1% FA. All data analysis was performed using Analyst 1.6 (ABSCIEX).
2D NMR Spectroscopy and 3D Structure Calculations. MoVIB and analogue peptides samples were 
prepared at 2 mg/ml in 90% H2O/10% D2O or 100% D2O (pH 5.0) for Nuclear Magnetic Resonance (NMR) spec-
troscopy studies. Two dimensional (2D) homonuclear 1H-1H total correlation spectroscopy (TOCSY), nuclear 
Overhauser effect (NOESY) and exclusive correlation spectroscopy (ECOSY) datasets, and a 2D heteronuclear 
1H-13C HSQC were recorded at 900 MHz on a Bruker Avance II spectrometer, equipped with a cryogenically 
cooled probe and processed using Topsin 3.0 (Bruker). Homonuclear data were recorded with 2048 data points 
in the direct dimension and 512 increments in the indirect dimension over a sweep-width of 12 ppm. The HSQC 
spectrum was recorded with an indirect dimension sweep-width of 106 ppm. Data analysis were performed 
using the Computer Aided Resonance Assignment (CARA) software56. Structural restraints derived from the 
NMR data included (i) Inter-proton distances derived from NOESY cross-peak intensities in spectra recorded 
in either H2O or D2O with a mixing time of 100 ms. (ii) Backbone dihedral angles (Phi and Psi) derived from a 
TALOS+57,58 analysis of Cα, Cβ, Hα and HN chemical shifts. (iii) Side chain dihedral angles (χ1) derived from 
analysis of 3JHαHβ coupling constants and intra residual NOE patterns (iv) Hydrogen-bond restraints derived 
from amide exchange rates and analysis of preliminary structures. Nuclear Overhauser effect (NOE) cross peaks 
were manually picked and subsequently calibrated and assigned automatically using the automatic assignment 
and structure calculation module of CYANA 3.059. For the final structures distance restraint lists from CYANA 
were used as input for simulated annealing and water minimization within CNS60, using protocols from the 
RECOORD database61, modified as described previously62. In the final round 50 structures were calculated, and 
the best 20 based on energies and quality of packing and geometry as judged by MOLPROBITY63 scores were 
chosen as representative of the solution structure of MoVIB. Figures were prepared using MOLMOL64.
Fluorimetric calcium imaging assays. For assay-guided fractionation and Cav selectivity characterization 
of MoVIA, MoVIB and mutant peptides, we used a cell-based calcium-imaging fluorimetric assay and the FLIPR 
platform. Human neuroblastoma SH-SY5Y cells were exposed to saturating concentrations of the Cav1 inhibitor 
nifedipine (10 µM) to isolate endogenous Cav2.240. For selectivity studies, we isolated Cav1.3 using saturating 
concentrations of Cav2.2 inhibitor CVID (3 µM). The small response remaining resistant was inhibited with sat-
urating concentrations of the Cav3 inhibitor mibefradil (30 µM)40. Briefly, we incubated SH-SY5Y cells with the 
Ca2+ dye Fluo 4 in the presence of Cav inhibitors for 30 min. Test toxins or controls were then added to the cells 
and responses monitored for 10 min. KCl stimulation buffer was then added to stimulate Cav channel opening 
and responses were recorded for an additional 5 min.
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Electrophysiological Recording from rat DRG neurons. Rat DRG neurons were enzymatically disso-
ciated from 10–16 day old Wistar rats, as described previously65. We performed whole-cell patch clamp recording 
using a MultiClamp 700B Amplifier (Molecular Devices). Data was digitalized with a Digidata 1322 A (Molecular 
Devices), filtered at 10 kHz and sampled at 100 kHz using pClamp 9.2 software. External recording solution con-
tained (in mM): 150 TEA-Cl, 2 BaCl2, 10 D-Glucose and 10 HEPES, adjusted to pH 7.4 with TEA-OH. The pipette 
electrodes had a final resistance of (1–3 MΩ), with an intracellular solution containing (mM): 140 CsCl, 1 MgCl2, 
5 BAPTA and 10 HEPES adjusted to pH 7.2 with CsOH. High voltage-activated (HVA) calcium channel currents 
were recorded using Ba2+ as the charge carrier and by measuring peak inward current amplitude elicited by 75 ms 
voltage steps to 0 mV from a holding potential of −70 mV. After current achieved steady state, we applied toxins 
to the physiological solution and plotted the peak inward current amplitude every 10 s. Series resistance were 
typically compensated at 70–80%, and leak and capacitance currents were subtracted using a −P/4 pulse protocol. 
We used selective Cav2.1 (P/Q-type) channel inhibitor Agatoxin-IVA (Abcam, Cambridge, United Kingdom) and 
CVIE, a selective Cav2.2 (N-type) channel inhibitor, to examine the selectivity profile of MoVIA and MoVIB in 
rDRG.
Radioligand Binding Assays. The cell membranes from SH-SY5Y and fish brain preparations and the radi-
oligand binding assays using ω-peptide GVIA radiolabelled at Tyr22 ([125I]-GVIA, Perkin Elmer) were performed 
as described previously26,40.
Partial Nerve Ligation-Induced Neuropathy in Rats. Animal experimentation followed the National 
Health and Medical Research Council Code of Practice for the Care and Use of Animals for Research in 
Australia, with the approval of the Royal North Shore Hospital Animal Care and Ethics Committee. Old male 
Sprague-Dawley rats (8–10 week, weighting 200–260 g) were housed three per enclosure and maintained on a 
standard 12 h light/dark cycle, with free access to food and water.
Tight partial nerve ligation of the sciatic nerve was carried out under isoflurane anaesthesia (1–3% in O2), as 
previously described32. To determine the establishment of neuropathy, PWTs were monitored using von Frey hair 
filaments and the up-down paradigm66. Briefly, a blinded experimenter applied six times von Frey hair stimulus 
of equal intensity (range 0.4–15 g) to each rat hind paw (at intervals of several seconds from time 0–4 h) and 
recorded the responses to stimuli (flinching and licking of the hind paws) and side effects. The average of these 
values per animal served as the pain related score, with no response to 15 g von Frey hair indicating the maximum 
possible effect (MPE). A visual score of 0–3, following previously described method32,46,67, was used to determine 
the degree of side effect.
One week after PNL surgery rats that developed significant neuropathy received intrathecal long-term poly-
ethylene lumbar catheters inserted between vertebrae L5 and L6. von Frey measurements were taken before to set 
baseline and after intrathecal treatment with vehicle or MoVIB. MoVIB (0.01–1 nmol, n = 3–6 animals/dose) was 
freshly dissolved in 0.9% saline and injected via the catheter in a volume of 10 µl, followed by 15 µl of 0.9% saline 
to wash the drug from the catheter dead space. Control animals received 0.9% saline injections of equal volume. 
Following intrathecal injections, we monitored rat behaviour at every hour over a 4-h period. After each exper-
iment, we checked the correct placement of catheters by injecting lignocaine (2%) and observing rapid bilateral 
hind limb paralysis. Animals that had no paralysis or lost weight after the catheter surgery were excluded from 
the analysis.
Statistical analysis. Sigmoidal concentration-response curves and IC50 values were calculated using 
GraphPad Prism v5.0, following a nonlinear regression analysis with a four parameter (variable Hill slope) equa-
tion fitted to the functional data and a three parameter (Hill slope of −1) equation fitted to radioligand binding 
data. To calculate average peak current values we used Microsoft Excel version 12.2.0. All results were expressed 
as the mean ± standard error of the mean (SEM) determined from triplicate data from at least 3 independent 
experiments. Statistical significance was determined using analysis of variance (ANOVA), with statistical sig-
nificance defined as p < 0.05, unless otherwise stated. We calculated the MPE values, from animal experiments 
applying the maximum pain threshold and maximum side effect score. ED50 values were calculated for % MPE 
data using a four parameter Hill slope with a variable slope, and compared using one-way or two-way ANOVA. 
When ANOVA tests were significant, we made post-hoc comparisons between drug/treatment groups and vehicle 
at individual time points using Bonferroni or Turkey adjustment for multiple comparisons.
Data Availability
All data generated or analysed during this study are included in this published article.
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